Long-term outcomes of patients with unfavorable stage I–II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation

Abstract

Management of stage I–II unfavorable risk Hodgkin lymphoma (HL) strives to reduce toxicity while maintaining tumor control. Compared to ABVD or BEACOPP, Stanford V chemotherapy contains less doxorubicin and bleomycin. We report long-term outcomes of patients with stage I–II classic HL with European risk factors treated with Stanford V combined modality therapy (CMT). From our institutional cancer registry, we identified 168 patients with ≥1 European risk factor treated with 8–12 weeks of Stanford V CMT and consolidative radiotherapy between 1990 and 2016. Outcomes were analyzed after classification by EORTC and GHSG unfavorable criteria. With median follow-up of 8.4 years, 10-year overall survival and progression-free survival for the entire cohort were 95% and 88%, respectively. Thirteen of 18 relapses were salvaged successfully. There were no cases of MDS or AML after primary therapy. Long-term outcomes of stage I–II unfavorable risk HL treated with Stanford V CMT are comparable to ABVD or BEACOPP regimens.

Keywords:

• Hodgkin lymphoma
• unfavorable
• early
• Stanford V

Disclosure statement

All other authors have no financial disclosures and no conflicts of interest.

Additional information

Funding

Y.Q was supported by Henry S. Kaplan Research Fund, Department of Radiation Oncology, Stanford University.